South Dakota Investment Council Buys New Position in The Cooper Companies, Inc. $COO

South Dakota Investment Council bought a new stake in The Cooper Companies, Inc. (NASDAQ:COO) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 1,100 shares of the medical device company’s stock, valued at approximately $78,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of COO. Zions Bancorporation National Association UT bought a new position in Cooper Companies in the 1st quarter valued at about $33,000. J.Safra Asset Management Corp grew its position in Cooper Companies by 204.8% in the 2nd quarter. J.Safra Asset Management Corp now owns 506 shares of the medical device company’s stock valued at $36,000 after buying an additional 340 shares in the last quarter. GKV Capital Management Co. Inc. bought a new position in Cooper Companies in the 1st quarter valued at about $40,000. Assetmark Inc. grew its position in Cooper Companies by 357.8% in the 2nd quarter. Assetmark Inc. now owns 618 shares of the medical device company’s stock valued at $44,000 after buying an additional 483 shares in the last quarter. Finally, Larson Financial Group LLC grew its position in Cooper Companies by 1,071.0% in the 1st quarter. Larson Financial Group LLC now owns 726 shares of the medical device company’s stock valued at $61,000 after buying an additional 664 shares in the last quarter. Institutional investors own 24.39% of the company’s stock.

Wall Street Analysts Forecast Growth

COO has been the subject of a number of recent analyst reports. Wells Fargo & Company decreased their target price on shares of Cooper Companies from $93.00 to $72.00 and set an “overweight” rating for the company in a research report on Thursday, August 28th. Piper Sandler reduced their price objective on shares of Cooper Companies from $105.00 to $83.00 and set an “overweight” rating for the company in a research report on Thursday, August 28th. The Goldman Sachs Group set a $64.00 price objective on shares of Cooper Companies and gave the company a “sell” rating in a research report on Wednesday, October 1st. Morgan Stanley set a $76.00 price objective on shares of Cooper Companies and gave the company an “equal weight” rating in a research report on Thursday, August 28th. Finally, Needham & Company LLC restated a “buy” rating and set a $94.00 price objective on shares of Cooper Companies in a research report on Thursday, August 28th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Cooper Companies presently has an average rating of “Moderate Buy” and an average price target of $84.77.

Cooper Companies Price Performance

COO stock opened at $69.08 on Wednesday. The company has a current ratio of 2.12, a quick ratio of 1.24 and a debt-to-equity ratio of 0.29. The Cooper Companies, Inc. has a one year low of $61.78 and a one year high of $107.84. The firm has a market capitalization of $13.73 billion, a PE ratio of 34.03, a P/E/G ratio of 1.83 and a beta of 1.02. The firm has a 50-day moving average of $69.20 and a two-hundred day moving average of $72.81.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings data on Wednesday, August 27th. The medical device company reported $1.10 EPS for the quarter, beating analysts’ consensus estimates of $1.07 by $0.03. Cooper Companies had a net margin of 10.08% and a return on equity of 9.82%. The company had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same period in the prior year, the firm earned $0.96 earnings per share. The business’s quarterly revenue was up 5.7% on a year-over-year basis. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. On average, analysts forecast that The Cooper Companies, Inc. will post 3.98 earnings per share for the current year.

Cooper Companies announced that its Board of Directors has initiated a stock repurchase program on Wednesday, September 17th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical device company to buy up to 15.4% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

Insider Activity at Cooper Companies

In other Cooper Companies news, Director Lawrence Erik Kurzius acquired 2,000 shares of the business’s stock in a transaction that occurred on Monday, September 29th. The shares were purchased at an average price of $68.39 per share, with a total value of $136,780.00. Following the completion of the transaction, the director owned 5,777 shares in the company, valued at $395,089.03. The trade was a 52.95% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Albert G. White III acquired 10,000 shares of the stock in a transaction dated Friday, September 5th. The stock was bought at an average price of $68.39 per share, for a total transaction of $683,900.00. Following the purchase, the chief executive officer owned 226,151 shares of the company’s stock, valued at $15,466,466.89. The trade was a 4.63% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders bought 17,975 shares of company stock valued at $1,216,346. Corporate insiders own 1.98% of the company’s stock.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.